- Conditions
- Locally Advanced or Metastatic Malignant Solid Tumors
- Interventions
- enfortumab vedotin, pembrolizumab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Locally Advanced or Metastatic Solid Tumor
- Interventions
- Rebastinib, Carboplatin
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- San Francisco, California • Santa Monica, California • Chicago, Illinois + 6 more
- Conditions
- Metastatic Solid Tumor Cancers, Locally Advanced Solid Tumor Cancers
- Interventions
- Expectations Survey (CanCORS), Values Survey (Serious Illness Care Program), Functional Assessment of Cancer Therapy-General (FACT-G), NCCN Distress Thermometer, Hospital Anxiety and Depression Scale (HADS), Quality of Communication (QOC), visits with a supportive care clinician
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
- Interventions
- Lirafugratinib
- Drug
- Lead sponsor
- Elevar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 4 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cilengitide
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Locally Advanced / Metastatic Solid Tumors
- Interventions
- CR-001
- Drug
- Lead sponsor
- Crescent Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more
- Conditions
- Advanced Melanoma and Normal or Impaired, Advanced Melanoma
- Interventions
- AB821
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
- Interventions
- PF-06801591
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more
- Conditions
- Neoplasms
- Interventions
- RG4733
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New Brunswick, New Jersey + 2 more
- Conditions
- Solid Tumor, Cancer, Carcinoma
- Interventions
- KHK2455, Mogamulizumab
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Albuquerque, New Mexico • Houston, Texas
- Conditions
- Solid Tumors
- Interventions
- Atezolizumab, Cergutuzumab Amunaleukin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • New York, New York • Nashville, Tennessee
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- JBI-802
- Drug
- Lead sponsor
- Jubilant Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Cincinnati, Ohio • Nashville, Tennessee + 1 more
- Conditions
- Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, FGFR3 Gene Fusions, Locally Advanced Unresectable Hepatocellular Carcinoma
- Interventions
- TYRA-430
- Drug
- Lead sponsor
- Tyra Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 6 more
- Conditions
- Solid Tumors, Metastatic Tumors
- Interventions
- OTS167IV
- Drug
- Lead sponsor
- OncoTherapy Science, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more
- Conditions
- Solid Tumors
- Interventions
- Atezolizumab, Cobimetinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
- Interventions
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 23
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bevacizumab, enzastaurin hydrochloride, diagnostic laboratory biomarker analysis, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Cancer, Cervical Cancer
- Interventions
- AGEN2034
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
- Conditions
- Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
- Interventions
- TST005
- Drug
- Lead sponsor
- Suzhou Transcenta Therapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Canton, Ohio • Dallas, Texas • San Antonio, Texas
- Conditions
- Unresectable Locally Advanced or Metastatic Cancer
- Interventions
- TAK-280
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • San Francisco, California • Minneapolis, Minnesota + 6 more
- Conditions
- Solid Tumors
- Interventions
- IBI3020
- Drug
- Lead sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Pheonix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
- Conditions
- Solid Cancers
- Interventions
- GDC-0623
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Sacramento, California • Oklahoma City, Oklahoma + 1 more